Idorsia Ltd (0RQE.IL)

1.9205 -0.0990 (-4.90%) At close: 02:35PM BST

Idorsia Ltd

Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 10 10
https://www.idorsia.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jean-Paul Clozel M.D.	CEO & Exec. Director	1.38M	N/A	1955
Mr. André C. Muller	Exec. VP & CFO	N/A	N/A	1963
Dr. Martine Clozel	Exec. VP & Chief Scientific Officer	N/A	N/A	1955
Mr. Andrew C. Weiss	Sr. VP and Head of Investor Relations & Corp. Communications	N/A	N/A	1968
Mr. Julien Gander L.L.M.	Sr. VP, Group Gen. Counsel & Company Sec.	N/A	N/A	1979
Mr. Alexander Khatuntsev	Sr. VP & Head of Global HR	N/A	N/A	1978
Dr. Guy Braunstein M.D.	Exec. VP & Chief Medical Officer	N/A	N/A	1956
Mr. Olivier Lambert	Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance	N/A	N/A	1966
Mr. Markus A. Riederer	Sr. VP & Head of Drug Discovery Biology	N/A	N/A	1962
Mr. Christoph Boss	Sr. VP & Head of Drug Discovery Chemistry	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Corporate governance

Idorsia Ltd’s ISS governance QualityScore as of 1 October 2023 is 2. The pillar scores are Audit: 10; Board: 2; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.